Getting your player ready...
LOUISVILLE — Replidyne Inc., a Louisville-based biopharmaceutical company, announced Wednesday it is restructuring and will reduce employee headcount by approximately 80 percent, to five, in September and October.
Replidyne will also suspend further development activities of anti-infective and anti-bacterial compounds. Kenneth J. Collins, president and chief executive, said the company will review its strategic alternatives, including a merger or acquisition of the company or sale of its development programs.
